HKU Scholars Hub: Browsing DSpace

Browsing by Author Gane, E

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 44 to 63 of 72 < previous next >

Title	Author(s)	Issue Date	Views
Reduction in Hepatitis B Viral DNA and Hepatitis B Surface Antigen Following Administration of a Single Dose of VIR-3434, an Investigational Neutralizing Monoclonal Antibody: First Experience in a Population With Viremia Proceeding/Conference:The Liver Meeting 2022: American Association for the Study of Liver Diseases (AASLD) (04/11/2022-08/11/2022, Washington, USA)	Agarwal, K Yuen, MF Wedemeyer, H Cloutier, D Shen, L Arizpe, A Gupta, SV Fanget, M Seu, L Cathcart, AL Lau, AH Hwang, C Gane, E	31-Oct-2022
Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression Proceeding/Conference:Journal of Hepatology	Yuen, RMF Berliba, E Sukeepaisarnjaroen, W Strasser, S Tangkijvanich, P Holmes, J Leerapun, A Jucov, A Thi, EP Wattamwar, T Sofia, MJ Sevinsky, H Gray, K Antoniello, D Eley, T Picchio, G Sims, K Gane, E	2021	14
Reply Journal:Hepatology	Wat, C Gane, E Yuen, RMF Pavlovic, V Mueller, H Krippendorff, B-F Grippo, JF Ottosen, S	2022
Resistance monitoring data from treatment-naïve chronic HBV infected patients treated for 28 days with a new class a core protein allosteric modulator RO7049389 monotherapy Proceeding/Conference:Journal of Hepatology	Zhou, X Kazma, R Meinel, D Zhou, Y Yuen, RMF Gane, E Schwabe, C Tanwandee, T Cao, L Zhou, J Bo, Q	2020	28
RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBVactivity in chronic hepatitis B patients and is safe and well tolerated Proceeding/Conference:Journal of Hepatology	Gane, E Liu, A Yuen, RMF Schwabe, C Bo, Q Das, S Goa, L Zhou, X Wang, Y Coakley, E Jin, Y	2018	91
RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients Proceeding/Conference:Journal of Hepatology	Gane, E Yuen, RMF Bo, QY Schwabe, .C Tanwandee, T Das, S Jin, YY Guo, L Zhou, X Wang, YF Feng, S Meinel, D Zhu, MF	2019
RO7049389, a core protein allosteric modulator, is safe and well tolerated in healthy volunteers and demonstrates potent anti-HBV activity in a phase 1 trial Proceeding/Conference:Journal of Viral Hepatitis	Gane, E Liu, A Yuen, RMF Schwabe, C Bo, Q Das, SB Goa, L Zhou, X Wang, Y Coakley, E Jin, Y	2018
RO7062931 antisense oligonucleotide phase 1 study demonstrates target engagement in patients with chronic hepatitis B on established nucleos(t)ide therapy Proceeding/Conference:Journal of Hepatology	Yuen, RMF Gane, E Kim, DJ Chan, H Surujbally, B Pavlovic, V Triyatni, M Grippo, J Kim, HJ Leerapun, A Lim, TH Lim, YS Tanwandee, T Kim, W Cheng, W Hu, TH Wat, C	2020
Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results Proceeding/Conference:Journal of Hepatology	Gane, E Lim, YS Cloutier, D Shen, L Cathcart, A Ding, X Pang, P Huang, S Yuen, RMF	2021
Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use Proceeding/Conference:Journal of Hepatology	Gane, E Seto, WKW Janssen, H Carantu, FA Kim, HJ Abdurakhmanov, D Nishiguchi, S Andrzej, H Bae, H Mo, S Suri, V Gaggar, A Flaherty, JF Kao, JH Brunetto, M Ferret, MB	2018	88
Safety, pharmacokinetics (PK), and antiviral activity of the capsid assembly modulator (CAM) ALG-000184 in Asian and non-Asian subjects with chronic hepatitis B (CHB) Proceeding/Conference:APASL 2022, Seoul, Korea, 30 Mar - 3 Apr 2022. Hepatology International	Yuen, RMF Agarwal, K Gane, E Jucov, A Schwabe, C Le, K Massetto, B Westland, C Zhang, QL Blatt, L Lin, T-I Chanda, S Mcclure, M Fry, J	2022
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial Journal:The Lancet Gastroenterology & Hepatology	Yuen, RMF Zhou, X Gane, E Schwabe, C Tanwandee, T Feng, S Jin, YY Triyatni, M Lemenuel-Diot, A Cosson, V Xue, ZH Kazma, R Bo, QY	2021
Safety, tolerability and pharmacokinetics (pk) of single and multiple doses of alg-010133, an s-antigen transport inhibiting oligonucleotide polymer (stops) for the treatment of chronic hepatitis B Proceeding/Conference:Journal of Hepatology	Gane, E Yuen, RMF Yogaratnam, J Le, K Vuong, J Christopher, W Gohil, V Schwabe, C Agarwal, K Jucov, A Liu, JW Lin, T-I Blatt, L Chanda, S McClure, M Fry, J	2021	9
Safety, tolerability, pharmacokinetics and antiviral activity of AL-3778, a first-in-class, HBV core assembly modulator alone and in combination with peginterferon-alpha 2A, in treatment naive HBeAg-positive chronic hepatitis B patients Proceeding/Conference:Hepatology International	Kennedy, W Yuen, RMF Kim, DJ Weilert, F Chan, HLY Lalezari, J Hwang, SG Nguyen, T Westland, C Kakuda, T Brown, N Klumpp, K Flores, L Talloen, W Lenz, O Gane, E van Remoortere, P Chandra, S Fry, J	2017	116
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors Proceeding/Conference:Journal of Hepatology	Gane, E Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O De Ridder, F Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2021	1
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B (CHB) shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors Proceeding/Conference:APASL 2022, Seoul, Korea, 30 Mar - 3 Apr 2022. Hepatology International	Gane, E Locarnini, S Lim, TH Strasser, SI Sievert, W Cheng, W Thompson, AJ Given, BD Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont, M Lenz, O Ridder, FD Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, R Yuen, RMF	2022
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold Proceeding/Conference:Journal of Hepatology	Yuen, RMF Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Gane, E	2019	73
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment Proceeding/Conference:Journal of Hepatology	Gane, E Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2020	3
Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial Proceeding/Conference:Hepatology	Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Chen, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N and the GLOBE Study Group, .	2005
Telbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: Results from the GLOBE study Proceeding/Conference:Journal of Hepatology	Thongsawat, S Lai, CL Gane, E Chao, G Fielman, B Brown, N GLOBE Investigator Group, .	2006	117

Showing results 44 to 63 of 72 < previous next >